AB Science announces that it has received the first authorization to resume patient enrollment in the confirmatory Phase 3 study of masitinib (AB19001) in ALS

NEXT STORY
Pediatric MRI Market ($5.68Bn by 2028) Growth Forecast at 7.5% CAGR During (2021-2028) – COVID-19 Impact and Global Analysis by TheInsightPartners.com
PREV STORY
Medical Second Opinion Market Size Worth USD 9751.58 Million by 2027 at 15.8% CAGR – Report by Market Research Future (MRFR)
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

BeyondSpring Provides Operational Updates and First-Quarter 2018 Financial Results

NEW YORK, June 21, 2018 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the Company) (NASDAQ:BYSI), a ...

author_avatar
NASDAQ Market News

Loxo Oncology to Present at Upcoming Investor Conferences

STAMFORD, Conn., Aug. 30, 2017 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical ...

author_avatar
NASDAQ Market News

Sun BioPharma Files Form 10-Q for Second Quarter 2016 and Provides Business Update

Initiated second cohort in Phase 1 clinical study of SBP-101; first-in-class proprietary compound designed ...

author_avatar
NASDAQ Market News